Unidentified Speaker Person The Legislature could consider revising the current policy to ensure the board defers to judge interpretations of the law Due to the board's enforcement actions
A new and more powerful obesity drug was coming, and some people, it turns out, could not wait
Musculoskeletal & Tendon Models A growing body of preclinical literature has examined BPC-157 in models involving tendon, ligament, bone, and muscle tissue
The STEP trials for semaglutide 2.4 mg (Wegovy) showed: Average weight loss of approximately 15% of body weight over 68 weeks One-third of participants lost 20% or more of body weight Significant reductions in waist circumference, blood pressure, and cardiovascular risk markers The SURMOUNT trials for tirzepatide (Zepbound) showed even more impressive results: Average weight loss of 20-25% at the highest dose (15 mg) over 72 weeks More than half of participants lost 20% or more of body weight Significant improvements in type 2 diabetes markers, blood pressure, and lipid profiles The head-to-head comparison is clear
"Why Blue Cross Blue Shield is rolling back coverage of GLP-1 drugs." wbur.org Anthem Blue Cross California
Commercially available primer-probe sets were used (Applied Biosystems, Waltham, Massachusetts, USA)